Oncology and Hematology

113-128 of 173

• 

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  MinuteCE®

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  Susana Campos, MD, MPH

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  MinuteCE®

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  Wenxin Xu, MD; Sandy Srinivas, MD

  1.25 program credits

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  MinuteCE®

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  Susana Campos, MD, MPH; Ritu Salani, MD, MBA

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Gynecologic Cancer

  Susana Campos, MD, MPH; Nicoletta Colombo, MD

  1.00 credit 10 episodes

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Ritu Salani, MD, MBA

  1.00 credit 10 episodes

• 

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging targeted therapy combination strategies in genitourinary malignancies

  Ignacio Duran, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  1.25 program credits

• 

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging immunotherapy combination strategies in genitourinary malignancies

  Sandy Srinivas, MD

  1.25 program credits

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  MinuteCE®

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  MinuteCE®

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  MinuteCE®

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  Ritu Salani, MD, MBA; Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 credits 10 episodes

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  • 

    

    Sandy Srinivas, MD

  1.25 credits 10 episodes

• 

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  MinuteCE®

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  Nicoletta Colombo, MD; Ritu Salani, MD, MBA

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  MinuteCE®

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  RestartResume

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  MinuteCE®

  Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  MinuteCE®

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  MinuteCE®

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  Luis Paz-Ares, MD, PhD; Helena Yu, MD

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• Previous
• 1
• 2
• …
• 6
• 7
• 8
• 9
• 10
• 11
• Next